Project Grant R43AI186768
Award Date
8/1/24
Completion Date
7/31/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Lucerna Inc. (J3MWGA6WFCG3)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Brooklyn, NY 11226, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $288,515 Project Grant to Integral Molecular Inc. to develop a Rapid Reporter Virus (RRV) assay. This innovative assay aims to provide a more streamlined, safe, and scalable method for assessing virus infection and neutralization, compared to traditional live virus Plaque Reduction Neutralization Tests (PRNT). The goal is to enable more...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baebies, Inc., a Durham, North Carolina-based medical diagnostics company. This funding will support the development of a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs) and reduce overtreatment, thereby helping to prevent the emergence of antibiotic-resistant STI strains....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $807,664 to Heligenics, Inc. to develop a high-throughput screening platform for identifying novel bifunctional protein chimeras as potential biologic drug candidates. The key activities under this 3-year award include: 1) Evaluating a library of over 50,000 bifunctional interferon chimeras to isolate more potent...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $188,438 Project Grant (R21AI181613) to Yale University to develop a high-throughput, cell-free screening system to identify small molecules that can inhibit the interaction between the HIV Rev protein and its response element (Rev-Rev interaction). The goal is to discover potential first-in-class anti-Rev therapeutics that can interfere with an...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,361,442 to Emory University to develop an economical, rapid molecular test for detecting Hepatitis C Virus (HCV) and HIV from whole blood. The key objectives are: Adapting and automating RNA sample extraction and stabilization (RNAES) technology to extract and stabilize HCV/HIV RNA from capillary whole blood,...
This Project Grant award, valued at $1,528,846.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop an exclusive liquid repellency-based microfluidic system for transformative, next-generation phenotypic antimicrobial susceptibility testing (AST). The key objectives are to: 1) enable direct AST using original clinical isolates without time-consuming expansion...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $297,761 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Biological Mimetics, Inc. to develop a sensitive, rapid, and affordable CRISPR-based diagnostic test for malaria parasites. The project aims to create an instrument-free, simple-to-run diagnostic that requires no advanced training and is suitable for resource-limited regions. Key objectives include optimizing the isothermal amplification...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,473,521.00 in funding to the Scripps Research Institute in La Jolla, California. The grant supports the development of a novel therapeutic approach to inhibit SARS-CoV-2 infection and COVID-19 disease. The proposed strategy involves delivering a tailored RNA encoding the diphtheria toxin fragment A (COV-2...